AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...
A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...
After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for ...
AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application for accelerated approval in the US for datopotamab deruxtecan for the treatment of adult patients with locally ...
The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...
Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...
Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs ...
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...
Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca and Daiichi Sankyo's new ...
TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 ...
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback